Listen
ECALTA (anidulafungin), echinocandin
INFECTIOUS DISEASES - New indication
Opinions on drugs -
Posted on
Dec 15 2016
Reason for request
Extension of indication
- ECALTA now has Marketing Authorisation in the curative treatment of invasive candidiasis in adults with neutropenia.
- Given the low level of proof, with respect to the alternatives and the absence of comparative study versus another echinocandin or liposomal amphotericin B, ECALTA has no role in the therapeutic strategy in invasive candidiasis in adults with neutropenia.
- Its benefit as an alternative to other echinocandins (caspofungin or even micafungin) has not been established in this indication.
Clinical Benefit
| Substantial |
- |
| Insufficient |
Clinical Added Value
| Not applicable |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
